Solid Biosciences Set to Report Whether Gene Therapy Losses Are Narrowing on Schedule

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Solid Biosciences typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors can react to results, while Day +1 captures follow-through momentum.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 1.80% and Day +1 move of 6.21%. The Day +1 reaction has been particularly pronounced, with an average intraday range of 10.63%, more than double the typical Day 0 range of 5.90%.

The directional pattern has been mixed but skewed negative in recent quarters. The most recent earnings (August 2026) saw minimal Day 0 movement (-0.23%) but a 3.67% decline on Day +1. The May 2026 report showed initial strength (+0.52% Day 0) that reversed sharply to a 4.40% drop on Day +1. The most dramatic move came in November 2025, when the stock fell 3.53% on Day 0 and extended losses to 15.29% by Day +1.

Investors should prepare for substantial two-day volatility, with the Day +1 session historically delivering the larger move as the market digests clinical updates and management commentary from the earnings call. The wide intraday ranges suggest active trading and position adjustments as investors reassess the pipeline's risk/reward profile.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.85% (±$0.43) through the November 20 expiration, which is slightly above the historical average Day 0 move of 1.80% but below the average Day +1 move of 6.21%. This suggests options traders are anticipating volatility in line with recent post-earnings patterns, though the 21-day window to expiration captures more than just the immediate earnings reaction.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish consensus on Solid Biosciences, with an average rating of 4.73 out of 5.00 (between Buy and Strong Buy). The current breakdown shows 12 Strong Buy ratings, 2 Moderate Buy ratings, and 1 Hold rating, with zero sell recommendations. This represents an improved sentiment trend from one month ago, when the company had 11 Strong Buys, 2 Moderate Buys, and 1 Hold.

The average price target of $18.71 implies substantial upside of approximately 202% from the current price of $6.20. Analyst targets range from a low of $11.00 to a high of $26.00, reflecting varying assumptions about the commercial potential of the company's gene therapy pipeline. The recent upgrades and target increases—including Cantor Fitzgerald's $26 target and H.C. Wainwright's reiterated $25 target—underscore growing confidence in the SGT-003 and SGT-212 programs.

The strengthening consensus reflects optimism around upcoming clinical catalysts, particularly the INSPIRE study data readout and the FALCON trial's progress in Friedreich's ataxia. With 9 analysts having revised earnings estimates upward for the upcoming period, the Street appears increasingly confident in the company's ability to execute on its development timeline despite the current cash burn rate. The wide target range, however, highlights the binary nature of biotech investing, where clinical success or setbacks can dramatically alter valuation assumptions.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 72% Sell signal, representing a significant deterioration from 56% Sell one week ago and 8% Sell one month ago. This sharp weakening in technical sentiment reflects mounting downside pressure as the stock approaches earnings.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates near-term momentum has turned decisively negative heading into the earnings release
• Medium-term (50% Sell): Moderate sell signal suggests intermediate-term weakness, though less severe than the short-term picture
• Long-term (50% Sell): Moderate sell signal reflects persistent weakness in the longer-term trend structure

Trend Characteristics: The technical environment shows Average strength with a Strengthening direction, indicating the sell signal is gaining conviction as downside momentum builds.

The stock is currently trading at $6.20, positioned below all major moving averages except the 10-day. Specifically, SLDB trades below its 5-day ($6.21), 20-day ($6.28), 50-day ($7.81), 100-day ($8.34), and 200-day ($7.66) moving averages, while sitting marginally above the 10-day ($6.19). This configuration—particularly the distance below the 50-day and 100-day averages—signals a stock in a clear downtrend with overhead resistance at multiple levels.

The technical setup heading into earnings is decidedly cautionary. With the stock trading 20.6% below its 50-day moving average and 25.7% below its 100-day average, SLDB faces significant overhead resistance even if earnings deliver positive surprises. The 50-day moving average at $7.81 represents the first major hurdle, followed by the 100-day at $8.34. The deteriorating Barchart Opinion—shifting from 8% Sell to 72% Sell in just one month—suggests technical traders have turned increasingly bearish. For bulls, a strong earnings beat and positive clinical updates would need to be substantial enough to overcome this negative technical backdrop and reclaim the 20-day moving average at $6.28 as a first step toward trend reversal.